Compare Amylx Pharmaceuticals Inc (AMLX) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs FuelCell Energy Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.6 (market cap $2.64B), while FuelCell Energy Inc trades at $22.15 (market cap $1.54B). The key difference: Amylx Pharmaceuticals Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | FCEL | |
|---|---|---|
Market Cap | $2.64B | $1.54B |
Sector | Health | Industrials |
52-Week High | $24.19 | $36.01 |
52-Week Low | $7.82 | $3.92 |
Enterprise Value | $2.39B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
FCEL trades at $21.32, up 7.51% in the last 24 hours, with a bearish technical signal and RSI near oversold levels. The company reported a net loss of $187.9 million in 2025, with negative gross and net income margins, though revenue grew to $158.16 million. Recent news highlights partnerships with Siemens and focus on AI-driven power demand, but cash flow from operations remains negative.
The outlook is mixed: analyst consensus is split between Buy and Hold with a $20.75 price target, slightly below current price. Key risks include persistent losses, high cash burn, and competitive pressures in the hydrogen sector. Upside potential hinges on execution of growth initiatives and profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
